title: Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients.
abstract: Conversion to tacrolimus (Tac) to once daily (Tac-O) formulation is commonly followed by a 20% reduction in Tac trough levels in the first month. It is not associated with modifications of renal function but there is the issue of its effects on inflammatory cytokines and on subclinical rejection. The aim of our study was to evaluate long-term interleukins (IL)-2 profiles in stable renal transplant patients after Tac-O conversion. We enrolled 10 stable kidney transplant patients converted to Tac-O. Tac trough levels, serum creatinine concentrations, glomerular filtration rate using the Modification of Diet in Renal Disease formula, C-reactive protein, IL-2 levels, and clinical assessments were performed monthly for 6 months before and 12 months after conversion. Despite the significant reduction in Tac trough levels, we did not observe alterations suggestive of clinical or subclinical acute rejection.
authors.affiliation: Department of Clinical Medicine, Nephrology and Dialysis Unit, 1st Faculty of Medicine and Surgery, Sapienza University of Rome, Rome, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Umbro
authors.forename: F
authors.initials: F
authors.lastname: Tinti
authors.forename: A
authors.initials: A
authors.lastname: Mecule
authors.forename: A
authors.initials: A
authors.lastname: Bachetoni
authors.forename: L
authors.initials: L
authors.lastname: Poli
authors.forename: A
authors.initials: A
authors.lastname: Pignatelli
authors.forename: C
authors.initials: C
authors.lastname: Alessandri
authors.forename: F
authors.initials: F
authors.lastname: Fiacco
authors.forename: M
authors.initials: M
authors.lastname: D'Alessandro
authors.forename: V
authors.initials: V
authors.lastname: Di Natale
authors.forename: P B
authors.initials: PB
authors.lastname: Berloco
authors.forename: G
authors.initials: G
authors.lastname: Valesini
authors.forename: A P
authors.initials: AP
authors.lastname: Mitterhofer
mesh_terms: D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D016030:Kidney Transplantation; D016559:Tacrolimus / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D007376:Interleukin-2; D016559:Tacrolimus